Goldenwell Biotech (GWLL) Equity Average (2020 - 2025)
Goldenwell Biotech filings provide 6 years of Equity Average readings, the most recent being -$90830.5 for Q3 2025.
- On a quarterly basis, Equity Average fell 887.6% to -$90830.5 in Q3 2025 year-over-year; TTM through Sep 2025 was -$90830.5, a 887.6% decrease, with the full-year FY2024 number at $18741.0, down 86.91% from a year prior.
- Equity Average hit -$90830.5 in Q3 2025 for Goldenwell Biotech, down from -$84228.0 in the prior quarter.
- In the past five years, Equity Average ranged from a high of $360802.0 in Q2 2021 to a low of -$90830.5 in Q3 2025.
- Median Equity Average over the past 5 years was $154470.5 (2023), compared with a mean of $144219.9.
- Biggest five-year swings in Equity Average: surged 43.46% in 2021 and later plummeted 887.6% in 2025.
- Goldenwell Biotech's Equity Average stood at $316483.5 in 2021, then tumbled by 30.71% to $219284.0 in 2022, then plummeted by 56.62% to $95122.5 in 2023, then plummeted by 114.72% to -$14001.0 in 2024, then plummeted by 548.74% to -$90830.5 in 2025.
- The last three reported values for Equity Average were -$90830.5 (Q3 2025), -$84228.0 (Q2 2025), and -$64429.5 (Q1 2025) per Business Quant data.